FIELD: pharmacology.
SUBSTANCE: presented method comprises: (a) cooling of initial suspension containing lipid component and protein component from the temperature in the first temperature range to the temperature in the second temperature range; (b) heating of the cooled suspension of stage (a) from the temperature in the second temperature range to the temperature in the first temperature range; (c) cooling of the mentioned heated suspension of stage (b) from the temperature in the first temperature range to the temperature in the second temperature range; and (d) repeating of the stages (b) and (c) at least once to prepare lipoprotein complexes.
EFFECT: presented inventions can be used to prepare homogeneous pharmaceutically acceptable drugs with less risk of adverse events due to contaminations during their use.
51 cl, 59 dwg, 19 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| A-I APOLIPOPROTEIN MIMETICS | 2010 |
|
RU2532222C2 |
| RECONSTITUTED HDL FORMULATION | 2013 |
|
RU2669568C2 |
| TREATMENT OF MYOCARDIAL INFARCTION WITH REGENERATED HIGH-DENSITY LIPOPROTEIN | 2017 |
|
RU2798830C2 |
| CONCENTRATED THERAPEUTIC PHOSPHOLIPID COMPOSITIONS | 2010 |
|
RU2755902C2 |
| CONCENTRATED THERAPEUTIC PHOSPHOLIPIDE COMPOSITIONS | 2010 |
|
RU2642653C2 |
| TREATMENT OF APOLIPOPROTEIN-A1 RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO APOLIPOPROTEIN-A1 | 2009 |
|
RU2604489C2 |
| PHARMACEUTICAL COMPOSITIONS OF SUBSTITUTED QUINAZOLINONES | 2012 |
|
RU2640115C2 |
| RNA PARTICLES INCLUDING POLYSARCOZINE | 2019 |
|
RU2792644C2 |
| USING LCAT FOR TREATING ANAEMIA AND RED BLOOD CELL DISORDERS | 2010 |
|
RU2576838C2 |
| DRIED RECONSTITUTED VESICLES FOR PHARMACEUTICAL APPLICATION | 2007 |
|
RU2443412C2 |
